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A Review of Coronavirus Infection in the Central Nervous System
of Cats and Mice
Janet E. Foley and Christian Leutenegger
Feline infectious peritonitis (FIP) is a common cause of death in cats. Management of this disease has been hampered by difficulties
identifying the infection and determining the immunological status of affected cats and by high variability in the clinical, patho-
logical, and immunological characteristics of affected cats. Neurological FIP, which is much more homogeneous than systemic
effusive or noneffusive FIP, appears to be a good model for establishing the basic features of FIP immunopathogenesis. Very little
information is available about the immunopathogenesis of neurologic FIP, and it is reasonable to use research from the well-
characterized mouse hepatitis virus (MHV) immune-mediated encephalitis system, as a template for FIP investigation, and to
contrast findings from the MHV model with those of FIP. It is expected that the immunopathogenic mechanisms will have important
similarities. Such comparative research may lead to better understanding of FIP immunopathogenesis and rational prospects for
management of this frustrating disease.
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Feline infectious peritonitis (FIP) is a fatal, immune-me-diated disease produced as a result of infection of
macrophages by mutant feline coronavirus strains (FIPVs).
The severity of FIP is determined by virus strain and by
host-specific, partially heritable immune responses.1 The
causative agent, FIP virus (FIPV), is a macrophage-tropic
mutant of the ubiquitous feline enteric coronavirus
(FECV).2–4 These feline coronaviruses are closely related to
transmissible gastroenteritis virus (TGEV) of pigs and more
distantly related to MHV (a coronavirus of rodents), human
respiratory coronavirus, and others. As with most RNA vi-
ruses, a high rate of point or other small-scale mutations
and larger scale recombination events occur. Type II
FECVs are viruses that arise as a result of recombinations
between type I FECV and canine coronavirus (CCV). Type
II FECVs acquired a canine S gene and express a canine S
gene product.5 Mutations are common in the 7b open read-
ing frame (ORF) of both type I and type II FECVs and may
be associated with reduced virulence.4,6 The 7b ORF arose
in the FECV/CCV lineage and encodes a nonstructural se-
cretory glycoprotein of undetermined function, which is not
necessary for viral replication.7 Deletions, point mutations,
and frame-shift mutations leading to early truncation of the
3c ORF also are common.4,6 Because FIP-defining muta-
tions may occur in the S, 3c, and 7b genes, polymerase
chain reaction (PCR) with these genes as a target cannot
discriminate between benign FECV and fatal FIPV.2–4
Murine hepatitis virus shares most genes with the
FECVs, including M (membrane glycoprotein), E (small
From the School of Veterinary Medicine, Center for Companion
Animal Health (Foley), and the Department of Medicine and Epide-
miology (Foley, Leutenegger), University of California, Davis, CA.
Based on a presentation to the ACVIM annual meeting, neurology
section, May 2000.
Reprint requests: Janet Foley, DVM, PhD, School of Veterinary
Medicine, Department of Medicine and Epidemiology, Davis, CA
95616; e-mail: jefoley@ucdavis.edu.
Submitted September 5, 2000; Revised December 15, 2000; Ac-
cepted February 28, 2001.
Copyright  2001 by the American College of Veterinary Internal
Medicine
0891-6640/01/1505-0002/$3.00/0
membrane), N (nucleocapsid), and S (spike glycoprotein),
which is post-translationally modified to S1 and S2.8 The
MHV genome, however, also codes for an HE protein and
does not contain a 7b ORF. Mutations in the E and S pro-
teins lead to attenuation of MHV.9 A third coronavirus,
HCV-229E, has been implicated in neurological disease in
people.10
Clinical Manifestations of Coronaviral
Infection in the Central Nervous System (CNS)
FIPV in Cats
FIP occurs most frequently in cats younger than 3 years
of age from multiple-cat homes (shelters and breeding cat-
teries).11,12 One-quarter to one-third of cats with noneffusive
FIP have either primary neurological FIP or neurological
abnormalities as a part of their overall disease presentation
(Foley and Pedersen, unpublished data).13 The immunolog-
ical and pathological characteristics of neurological FIP,
however, are much more stereotypic than those of systemic
FIP. Thus, neurological FIP may be useful for studying ba-
sic mechanisms of FIP pathogenesis. The extent to which
genetic differences among viral strains confer relative neu-
rotropism is unknown, but some cats with severe neurolog-
ical disease have mild or undetectable systemic disease.
Both neurological and generalized FIP may present first
as a nonspecific illness, with clinical signs including weight
loss, weakness, fever, and lethargy. Abdominal abnormali-
ties are detected commonly on physical examination of cats
with neurological FIP, including mesenteric lymphadenop-
athy and irregular splenic and renal surfaces.14,15 Common
historical findings in cats with neurological FIP include de-
mentia, pica, seizures, inappropriate elimination, inconti-
nence (fecal and urinary), and compulsive licking.15,16 Neu-
rological examination may identify ataxia, hyperesthesia,
reduced consciousness, hyperreflexia, crossed-extensor re-
flexes, reduced conscious proprioception, caudal paresis,
cerebellar-vestibular signs, or cranial nerve deficits.14,15,17–19
Ophthalmic lesions also are common in neurological FIP,
including anterior uveitis, keratic precipitates, flocculent de-
bris in the anterior chamber, retinitis, and anisocoria.15
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MHV in Mice and Rats
Murine hepatitis virus, like FIPV, can produce either sys-
temic infection or disease primarily affecting the liver.
Well-defined neurotropic genetic variants of MHV also oc-
cur, including a well-studied variant designated MHV-JHM,
which is responsible for progressive encephalomyelitis and
death in infected mice and rats. Intranasal or intracranial
inoculation of MHV-JHM in BALB/C or C57Bl/6 mice
leads to rapid, fatal encephalitis.20 The syndrome in survi-
vors (either because the virus is attenuated or the host is
resistant, vaccinated, or a pup from a vaccinated dams) con-
sists of chronic demyelination and hindlimb paralysis21 and
has been proposed as a model for multiple sclerosis.22 De-
terminants of neurovirulence are found in the MHV S
gene.23,24 A second variant of MHV, MHV-OBLV60, leads
to neuronal infection specifically in the anterior olfactory
bulb after intranasal challenge in mice.25
Pathology of Coronavirus-Associated
Neurological Disease
FIP Pathology
The definitive lesion of FIP is a pyogranuloma that re-
sults from immune-mediated phenomena secondary to co-
ronaviral infection of macrophages. The most common sites
are serosal, pleural, meningeal, ependymal, or uveal mem-
branes. In the earliest stages of abdominal FIP, diffuse al-
terations with activated mesothelial cells and a few coro-
navirus-infected macrophages or an exudative precipitate
may be detected on serosal surfaces.26 Larger pyogranulo-
mas become grossly visible, ranging from small lesions,
often on the renal capsular surface, to severe, generalized
miliary granulomatous lesions that distort renal surfaces,
disseminate throughout the omentum and gastrointestinal
serosa, and invade splenic and hepatic parenchyma. Gross
lesions of FIP in the CNS may be subtle, with ependymitis,
thickening and opacification of meninges, and ventricular
dilatation, usually in the fourth ventricle and least often in
the lateral ventricles.15 Lesions occur most commonly on
the ventral surface of the brain, often accompanied by sec-
ondary obstructive hydrocephalus.
Histopathologically, lesions in the brains of cats with FIP
consist of meningitis, ependymitis (ranging from mild ep-
endymal infiltration to complete effacement of the epen-
dymal lining by a heavy infiltrate of histiocytes and lym-
phocytes), periventriculitis, and choroiditis of varying se-
verity, often superficial and oriented around the ventricles,
with dense infiltrates of lymphocytes, plasma cells, neutro-
phils, and macrophages.14,15,27–31 Meningitis may be more
severe on the ventrocaudal surfaces of the brain, especially
at the base of the cerebellum and the brainstem, including
the medulla oblongata. In the meninges, the inflammatory
cells may have a predominantly perivascular distribution,
forming cuffs around arteries (periarteritis) and infiltrating
the wall of veins and venules (phlebitis), with exudation of
a cell- and protein-rich edema fluid, and periventricular re-
active astrocytosis. The inflammation may extend into the
superficial neuropil, as well as into cranial nerve roots.15 If
lesions are deep, they usually are perivascular with scat-
tered glial nodules.27 Hydrocephalus is seen in association
with leptomeningitis, meningeal fibrosis, accumulation of
cellular debris, and obstruction of the cerebrospinal fluid
flow.
Pathology of Neurotropic MHV
Pathologic lesions after MHV infection in the brains of
rats and mice are variable, depending on viral dose and
route of administration and rodent genotype, age, and im-
munological characteristics.32 In severe acute JHM enceph-
alitis, necrotizing lesions are found in the gray and white
matter, with axonal changes, including disintegration of
neurofilaments.32 Within the necrotic areas, perivascular
neutrophilic infiltrates occur especially in the subependyma,
choroid, and meninges. In acute MHV-A59 infection in
CD8 T-cell deficient mice, periventricular encephalitis oc-
curs with lymphocytic infiltration into the choroid plexus,
ependyma, and subependymal brain tissue.33 Lesions in
MHV-OBLV60 consist of local neuronal infection, some
mitral cell destruction, and T-cell inflammation with astro-
cytosis.25 Some evidence suggests a pathological compo-
nent of vasculitis, with mouse endothelial cell lines suscep-
tible to MHV-JHM exhibiting cytopathology within several
days of infection.34
The subacute to chronic immune-modulated pathological
changes that occur with manipulation of the MHV-JHM
system are particularly relevant to the murine model of FIP.
Depending on mouse strain and immunological status,
MHV-JHM produces meningeal inflammation associated
with T-cells and macrophages and demyelination but rela-
tively little disease in axons. Demyelination occurs within
and adjacent to areas of inflammation and astrocytic pro-
liferation.32,35 Neutrophils and monocytes have been ob-
served infiltrating through endothelial cell junctions and
participating in the phagocytosis of myelin debris.32 Peri-
vascular cuffing by macrophages is observed in chronic en-
cephalitis, as in FIP.
Neurotropic Coronavirus Entry into the CNS
and Cell Tropism
FIPV Access and Persistence in the CNS
The route of entry of FIPV into the CNS is unknown.
The FIPV virus probably travels hematogenously in mac-
rophages, and 1 study reported a cat with positive immu-
nohistochemical staining for FIPV in monocytes in blood
vessels of the choroid plexus.36 Once in the CNS, there is
little evidence that FIPV enters any cells other than mac-
rophages. Foley et al15 reported positive immunohistochem-
ical staining (by means of a mouse monoclonal antibody
against the FIPV N protein) for FIPV, primarily in macro-
phages in FIP granulomas but also in some lymphocytes.
Virus-infected cells were numerous in some areas of intense
ependymitis and choroiditis and free within the ventricular
lumen, with very few positive cells in the meningeal infil-
trates. No staining was observed in vascular basement
membranes or in cells of the neuropil. Macrophages in ne-
crotic regions and in the center of lesions often are not
infected with coronavirus.37
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Neurotropic MHV Entry into the CNS
Neurotropic MHV strains have several routes of entry
into the CNS. Some studies show that MHV-JHM travels
up the olfactory nerve and enters the CNS.38 This is not
surprising, because coronaviruses generally are epitheli-
otropic, and neurons share embryological origin with epi-
thelial cells. CNS infection with JHM also may occur after
peripheral infection and viremia.39,40 Receptors for neuro-
tropic human coronavirus HCV-229E have been detected
not only in human lung cells but also in human neuron,
astrocyte, and oligodendrocyte cell cultures.41 HCV-229E
also infects macrophages and endothelial cells, however,
suggesting hematogenous introduction into the CNS,40,42
similar to FIP.
Once inside the CNS, the major targets for MHV are
glial cells and neurons.35 Especially in neuroattenuated
strains, MHV-JHM infects primarily oligodendrocytes43 and
has been reported in astrocytes.44 MHV-4 infects mainly
neurons.20 Subsequent events in chronic disease pathogen-
esis include recruitment of inflammatory cells and the in-
teractions of immune cells with the virus-infected cells.
Macrophages, activated T-cells, and some B-cells may cross
into the intact CNS through the blood-brain barrier, with
the potential for major cytokine upregulation.45,46
The Immunopathogenesis of Neurologic
Coronavirus Infections
FIP Immunopathogenesis
After establishment of FIPV in the CNS, mechanisms of
disease are primarily immune-mediated, involving humoral
and cell-mediated immunity (CMI). Coronavirus-infected
macrophages can trigger massive complement activation
and deposition of C3 on affected surfaces, disseminated in-
travascular coagulopathy, vessel necrosis, and effusion.37,47–
49 However, immunopathogenic events in neurological FIP
have not been well described.
Antibodies in FIP
Both in systemic and neurological FIP, antibodies (es-
pecially to the spike protein) contribute to the opsonization
of viral antigen and have the capacity to mediate or enhance
disease.50–54 Antibodies to FECV and FIPV are identical.
Anti-FIPV IgG and IgM-producing B-cells are present in
FIP lesions, at the interface of healthy tissue and granulo-
mas, and in the serum and CSF of cats with neurological
FIP.26,37 Apparently, some antibody production occurs lo-
cally in the CNS, in response to viral antigen in the brain.
In one study, serum coronavirus titers of 16 cats with neu-
rological FIP were positive, with a median titer of 1 : 400,
whereas CSF titers were positive in 15 cats, with a median
titer of 1 : 100.15 Two cats had high protein concentrations
and increased cells, predominantly lymphocytes and neu-
trophils. The titer in CSF was not statistically correlated
with serum titer, and the ratio of serum : CSF titer was not
correlated with the serum : CSF protein ratio. If passive
leakage of protein from serum into the CSF were invoked
to explain the presence of antibodies, it would be expected
that the total protein : anti-FIPV IgG ratios would be similar
in both serum and CSF. In contrast, CSF IgG titers tended
to be proportionally much higher than serum titers. This
finding suggests that anti-FIPV IgG may have been pro-
duced in the tissues of the brain in response to a locally
replicating virus.
FIP Cell-Mediated Immunity and Cytokine Changes
Although almost nothing is known about the mechanism,
cell-mediated immunity has been hypothesized to be pro-
tective against FIP.50–54 CD4 T-cells commonly are ob-
served in FIP granulomas.37 During acute experimental
multisystemic FIP, apoptosis and T-cell depletion were ob-
served in the spleen and mesenteric lymph nodes.55 This
effect was induced by heat-treated effusion fluid (presum-
ably containing some cytokines) but not tissue culture fluid.
Likewise, little is known about the induction of cytokines
during the course of FIP. Preliminary findings suggest that
development of FIP appears to be associated with a switch
to predominantly Th2 immunity, with increases in IL-10
concentrations.56 Goitsuka et al57 described increases in IL-
6 and IL-1, but Gunn-Moore et al58 reported reductions in
TH2 and TH1 cytokines including IL-2, IL-4, IL-10, and IL-
12, which they attributed to general immunosuppression.
Mildly increased amounts of IL-1 mRNA are detected in-
consistently in association with lesions in cells of many
organs in cats with FIP.59 Roles of IL-1 in this setting may
include vascular endothelial activation, regulation of mac-
rophages, IL-8 and IL-6, and chemotaxis. IL-6 and IL-1
can increase B-cell growth and differentiation and could
exacerbate humoral contributions to the severity of FIP. The
inflammatory cytokines TNF-, IL-1, and IL-6 could cir-
cumvent the blood-brain barrier during systemic FIP, or
they could cross the blood-brain barrier after reorganization
of the endothelial actin cytoskeleton.60,61 No information is
available regarding cytokine production in neurological FIP,
and how cytokines in the CNS compare to those in abdom-
inal tissues of cats with generalized or effusive FIP is un-
known.
MHV Immunopathogenesis: Chronic Encephalitis
with Demyelination Is an Immune-Mediated Disease
MHV neurological disease can range from severe, acute,
necrotizing, rapidly fatal encephalitis to chronic immune-
mediated demyelination with little encephalitis, depending
on mouse strain, age, and immunocompetence. The appre-
ciation of the principal role of the immune system in pro-
ducing demyelination emerged from a series of experiments
performed over several decades. Profoundly immunosup-
pressed mice develop high concentrations of virus in the
CNS, but demyelination and clinical signs are minimal. Im-
munocompetent mice have variable or even low concentra-
tions of virus but develop marked disease. Immune recon-
stitution in immunocompromised mice results in the devel-
opment of severe demyelinating disease.
If mice are pretreated with passive infusions of antibod-
ies or T-cells or if they receive neuroattenuated MHV
strains, they develop chronic, but not fatal, disease after
MHV-JHM infection.62,63 Immunocompetent C57BL/6 mice
clear MHV-JHM virus from the brain but develop severe
immune-mediated demyelination and paralysis.22 In con-
trast, severe combined immunodeficient (SCID) mice have
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persistent viral loads but no neurologic impairment or de-
tectable lesions. Gamma-irradiated immunocompromised
mice similarly were resistant to chronic demyelination, but
reconstitution of the immune system with adoptive transfer
of splenocytes restored the immune-mediated lesions.64
Cytotoxic T-Lymphocytes (CTLs) and Apoptosis in
MHV
Both CD4 and CD8 T-cells apparently are required
to clear MHV from the CNS. CD8 T-cells are the pre-
dominant infiltrating leukocyte in Lewis rats with MHV-
JHM and paralytic disease,65 whereas infiltration in clini-
cally normal MHV-JHM–positive brown Norway rats con-
sists of CD4 cells. CTLs may kill some virally infected
cells and protect mice from fatal disease, but they do not
completely eliminate virus.66 When CD8-depleted mice
are reconstituted, virus load is reduced, and infection is not
detected in most infected cell types, except for oligoden-
droglial cells.66 Mice with nucleocapsid or spike protein-
specific CD8 T-cells develop chronic demyelinating dis-
ease.21,67 In the MHV-OBLV60 model, depletion of CD8
cells is associated with delayed clearance of OBLV60 (but
infected mice did recover).25 CTLs probably exacerbate le-
sions by contributing to tissue damage. MHV is relatively
labile genetically (a common characteristic of RNA virus-
es), and mutant strains with recognition sites that can evade
CTL-mediated viral killing apparently increase and become
the predominant viral strains in response to CTL-mediated
natural selection. This feature results in disease progression
in immunocompetent, but not immunosuppressed, hosts in-
fected with these mutants.68
Several studies have suggested that apoptosis may be im-
portant in clearing virus from the CNS. Specific CTL rec-
ognition promotes apoptosis of MHV-infected cells.69 In ex-
perimental allergic encephalomyelitis in rats, apoptosis ap-
pears to help control inflammation.70
CD4 Cells in MHV
The role of CD4 cells in MHV infection is also com-
plex. Nucleocapsid or spike protein-specific CD4 T-cells
have been shown to protect mice from coronaviral enceph-
alomyelitis in the absence of CD8 T-cells.71 If mice with
MHV-OBLV60 had CD8 but not CD4 cells, they de-
veloped persistent infection. If they were CD8 deficient,
but CD4 cells were normal, they had delayed clearance
of the virus, suggesting a primary role for CD4 cells in
clearing this virus.25 Sussman et al72 and Williamson and
Stohlman73 documented the requirement for CD4 cells for
clearance of JHM from mice. However, -irradiated mice
that were reconstituted with CD4 cells responded to
MHV-JHM challenge with earlier and more severe onset of
neurological disease.74 CD4 knockout mice had less in-
flammation (with fewer macrophages and microglial cells)
and less demyelination than did CD4 competent mice.75
Cytokine Changes in MHV
The presence of MHV-JHM in astrocytes triggers a cy-
tokine cascade that contributes to demyelination.76 Sun et
al77 documented production of TNF-, IL-1, and IL-6 by
astrocytes in the spinal cords of mice that were chronically
infected with MHV-JHM, localized to areas of virus infec-
tion and demyelination. TNF- and IL-6 are also produced
in the brains of acutely infected mice, but the major cell
producing these cytokines is the macrophage. These cyto-
kines may help recruit T-cells and monocytes and may in-
crease vascular permeability.78 IL-1 promotes leukocyte
adhesion to endothelial cells, and TNF- is toxic to oligo-
dendrocytes.63 The role of IL-6 is unclear. Effects attributed
to IL-6 include recruitment and activation of T-cells and
macrophages, expansion of CTLs, modulation of plasma
cell differentiation, increased vascular permeability, down-
regulation of acute phase proteins, and contributions to im-
mune-mediated destruction in the CNS.79–82
In a study of cytokine profiles in lethally compared to
sublethally affected mice with JHM, both TH1- and TH2-
type cytokines, including IFN-, IL-4, and IL-10, were in-
duced in all mice.83 In the mice that died, TNF- was in-
duced more rapidly, and IL-1 was increased. In mice with
nonlethal infections, IL-12 and IL-1 were increased, and
IL-6 was expressed early. Minor differences were observed
in the patterns of inflammation in IL-10–deficient compared
to syngeneic mice, but the outcome of infection (eg, mor-
tality and virus load) was not affected.84 These results, com-
bined with those of Sun et al,77 suggest that IL-1 may
allow mice to survive the early stages of the disease but
may not allow for clearance of chronic infection.
Interferon- also appears to be important for clearance of
MHV infection. IFN-–deficient mice developed persistent
JHM infection with increased clinical signs and mortality
compared to mice competent to produce IFN-.85 Antiviral
antibody and CTL responses were normal in IFN-–negative
mice, despite the fact that IFN- modulates antibody pro-
duction. Viral antigen occurred in oligodendrocytes and in
association with CD8 T-cells, suggesting that IFN- is nec-
essary for control of viral replication in oligodendrocytes.
Treatment of mice with anti-IFN- antibody increased the
mortality rate of mice, whereas immunotherapy with IFN-
reduced mortality and virus load.86
MHV-OBLV60 infection in immunocompetent mice in-
duced transient mRNA upregulation for cytokines IL-1, IL-
1, IL-6, TNF-, and IFN-.25 Nude mice differed in their
cytokine profiles in that they lacked mRNA for IFN-, where-
as concentrations of the other cytokines remained persistently
high. The authors suggested that the increased cytokines in
the nude mice were produced by CNS glial cells and possibly
CD4 and CD8 subsets. IFN- treatment of human neu-
ronal cell cultures markedly increased the susceptibility of
cells to infection with HCV-OC43 (although cells were sus-
ceptible to 229E without IFN- treatment).87 In this study, the
hypothesized role of IFN- was induction of MHC class I
expression. IFN- may increase superoxide dismutase and
protect against oxygen radicals, kill virus directly, and increase
the cytotoxicity of other effector cells.
The chemokine CRG-2 is expressed primarily by astrocytes
during MHV infection and co-localizes with areas of viral
RNA and demyelination.88 The function of CRG-2 is not
known, but this chemokine is also found in simian immuno-
deficiency viral (SIV) encephalitis89 and lymphocytic chorio-
meningitis.90
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Prospects for Immunomodulation of FIP with
Insight from the Mouse Model
With very little information available about the immuno-
pathogenesis of neurologic FIP, research performed in mice
can be used as a model for FIP and to contrast findings from
the MHV model with those in FIP. The immunopathogenic
mechanisms are expected to have important similarities, but
the demyelination that occurs in MHV is a more extensive
pathological sequela of coronaviral infection (but not more
fatal for the patient) than the focal granulomas that occur in
FIP. It can be hypothesized that in FIP, upregulation of cyto-
kines IL-1, IL-6, IFN-, and TNF- may be important in
mediation of destructive inflammation, but cytokines IL-6 and
IFN- may be important in controlling viral infection, despite
adverse inflammatory effects. Cytokine and chemokine alter-
ations in the brains of mice and cats with coronavirus infec-
tions may provide valuable clues to the immunopathogenesis
of these diseases, as well as possible diagnostic markers and
targets for immunological treatment of disease.
It is tempting to consider cytokine modulation in the treat-
ment of FIP, but this application is premature without infor-
mation regarding the cytokine profiles of affected cats. In ad-
dition to characterizing the concentrations of cytokines in the
CNS of cats with FIP, it will be important to describe the
timing of upregulated cytokine transcription. In mice with
HMV-JHM, treatment with recombinant IFN- resulted in re-
duced virus load in the liver but not in the brain.86 If specific
pro-inflammatory cytokines are found to be consistently high
in cats with neurological FIP, use of cytokine antagonists may
eventually be of benefit in treatment.
Successful management of FIP may consist of better meth-
ods of prevention as well as management of disease once it
occurs. A commercial FIP vaccine is available that consists of
a mucosally delivered, temperature-sensitive mutant form of
FIPV. The vaccine virus is supposed to undergo replication
only in outer oronasal cavities at low temperatures, thus trig-
gering protective antibodies but not FIP. A few controversial
studies have documented reduction in FIP as a result of vac-
cination.91,92 Many vaccinated cats, however, fail to serocon-
vert with either IgG or IgA (Foley and Pedersen, unpublished
data), and independent studies failed to identify vaccine effi-
cacy.93,94 Other vaccines, including DNA vaccines, have not
progressed beyond experimental stages either because of lack
of seroconversion, lack of protection, or both. In contrast with
FIP vaccines, vaccines against MHV have been shown to pro-
tect mice from challenge with virulent virus. A vaccine with
purified spike protein95 and synthetic S2 led to neutralizing
antibodies in vivo.96,97 Recombinant subunits against S in to-
bacco mosaic virus were given subcutaneously or intranasally
and were protective against MHV-JHM.98
The current standard of care for immunomodulation of FIP
is immunosuppressive doses of prednisone, to sustain an ac-
ceptable quality of life for as long as possible. The effects of
steroids include lymphocytolysis, inhibition of arachidonic
acid metabolism, reduction in cytokine RNA transcription, and
nitric oxide synthesis inhibition.99 Other potentially useful anti-
inflammatory drugs include antileukocyte antibodies and an-
tioxidants. These treatments are only palliative. A better un-
derstanding of the fundamental pathogenesis of FIP will be
necessary to offer better treatment and, ultimately, cure of this
disease.
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